Nov 27 (Reuters) - CervoMed Inc CRVO.O:
CERVOMED ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO NEFLAMAPIMOD BY U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA
CERVOMED INC - TO REPORT TOPLINE DATA FROM PHASE 2B DLB TRIAL IN DECEMBER 2024
Source text: ID:nGNX3pS5JY
Further company coverage: CRVO.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。